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Non-alcoholic fatty liver disease represents the most common chronic liver disease in obese children of industrialized
countries. Nowadays the first line of treatment of pediatric non-alcoholic fatty liver disease is based on dietary and
lifestyle intervention; however compliance to these interventions is very difficult to maintain in long term
period. This editorial discusses about docosahexaenoic acid treatment as possible novel approach for non-alcoholic
fatty liver disease in obese children. Docosahexaenoic acid may modulate the inflammatory response, improve insulin
sensitivity and could be effective in enhancing intestinal barrier integrity, essential to protect a healthy gut-liver axis.
Indeed alteration of gut microbiota composition and increased intestinal permeability may rise the exposure of
liver to gut-derived bacterial products, causing activation of signalling pathways implicated in liver inflammation
and fibrogenesis. This mechanism has been observed in vitro and animal models of non-alcoholic fatty liver
disease but also in a clinical study in adults. While evidence suggests that n-3 long-chain polyunsaturated
fatty acids supplementation may decrease liver fat in adults, in pediatric population only a study examined
this topic. In obese children with non-alcoholic fatty liver disease well designed randomized controlled trials
are needed to better clarify the possible efficacy of docosahexaenoic acid treatment, and underlying mechanisms,
to identify the optimal required dose and to evaluate if the docosahexaenoic acid effect is limited to the duration of
the treatment or it may continue after the end of treatment.
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Non-alcoholic fatty liver disease (NAFLD), considered as
liver manifestation of metabolic syndrome, represents
the most common chronic liver disease in obese chil-
dren of industrialized countries, with a reported preva-
lence of 3% to 10% in the general pediatric population
and reaching a prevalence of 80% in obese or overweight
children [1]. NAFLD is characterised by the pathological
accumulation of liver fat without relation to alcohol intake,
ranging from ‘simple’ liver steatosis to non-alcoholic stea-
tohepatitis (NASH). Significant complications of NAFLD
are represented by progression to liver fibrosis and cirrho-
sis [2]. Excess food intake and sedentary lifestyle, resulting
in obesity and insulin resistance, are important environ-
mental risk factors associated with NAFLD [1]. However
the complete pathogenesis remains unexplained and seems
to involve several factors. Recently, a great deal of attention* Correspondence: elvira.verduci@unimi.it
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unless otherwise stated.has been focused on the gut-liver axis malfunction [small
intestinal bacterial overgrowth (SIBO), intestinal dysbiosis,
and increased intestinal permeability (“leaky gut”)], consid-
ered as another key factor involved in development and
progression of NAFLD [2]. Indeed intestinal epithelium,
gut microbiota and dietary pattern are linked in different
ways. For example, a high fat diet can stimulate a proin-
flammatory microbiota and interfere with intestinal perme-
ability [2]. Alteration of gut microbiota composition and
increased intestinal permeability may rise the exposure of
the liver to gut-derived bacterial products, as lipopolysac-
charides (LPS), which could determine endotoxemia. Then,
endotoxemia can stimulate Toll-Like Receptors (TLR),
causing activation of signalling pathways implicated in liver
inflammation and fibrogenesis [3]. This mechanism has
been observed in vitro and animal models of NAFLD but
also a clinical study has shown that NAFLD in adults is as-
sociated with increased intestinal permeability and SIBO,
related to severity of liver steatosis [4]. Moreover, Giorgio
et al. [3] showed that intestinal permeability is increased. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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severity of liver disease, suggesting its important role
in NAFLD progression. Therefore it appears that intes-
tinal barrier integrity is essential to protect a healthy gut-
liver axis.
Nowadays the first line of treatment of NAFLD in obese
children is represented by dietary and lifestyle interven-
tion; however compliance to these interventions is very
difficult to maintain in long term period, especially in
pediatric population [1]. The aim of this editorial is to dis-
cuss the possible role of DHA in treatment of NAFLD in
childhood obesity with respect to current evidence.
Main text
Several studies showed that NAFLD is characterized by
a low total level of n-3 fatty acids, in turn associated with
steatosis, increased oxidative stress and NASH [5]. More-
over, from studies in NAFLD experimental models, it has
been shown that n-3 fatty acids may alter liver gene ex-
pression (switching intracellular metabolism from lipogen-
esis and storage to fatty acid oxidation and catabolism),
improve insulin sensitivity, have anti-inflammatory prop-
erties and reduce tumor necrosis factor levels [5].
Supplementation with n-3 long-chain polyunsaturated
fatty acids (LCPUFA), and in particular DHA, has been
experienced as potential treatment for obesity-related
NAFLD especially in adult population. Indeed, a recent
systematic review showed that n-3 LCPUFA (eicosa-
pentaenoic acid and docosahexaenoic acid) supplemen-
tation may decrease liver fat in adults [6]. Currently,
there is in literature only a study examining this topic in
pediatric age [7]. Indeed a randomized controlled trial
reported that DHA supplementation was associated with
improved liver steatosis in obese children with NAFLD
[7]. This study showed that DHA supplementation may re-
duce liver hyperechogenicity in children with NAFLD after
6 months of treatment, with comparable effect using a
dose of 250 mg/day or 500 mg/day of DHA. The improve-
ment in echogenicity observed at 6 months remained un-
changed also after 24 months of treatment. Hovewer, it
should be pointed out that in this study the results were
obtained using liver ultrasound sonography test (US) only
and caution has to be paid in inferring any definitive con-
clusion. Indeed Chemical shift magnetic resonance imaging
(MRI) (opposed-phase imaging) should be also considered
for its recognized its ability to quantify hepatic fat content
accurately, and in turn to identify fat regression or accumu-
lation over time in children with NAFLD [8,9].
The potential protective effect of DHA has been sug-
gested also from a retrospective study evaluating early
type of feeding (breastfed versus formula-fed and duration
of breastfeeding) in a cohort of children with NAFLD
[10]. It has been speculated that DHA, delivered by hu-
man milk after prolonged lactation, could be protectiveagainst progression of the liver disease from simple steato-
sis to steatohepatitis and fibrosis (NASH) acting as peroxi-
some proliferator-activated receptors agonist (PPAR-agonist),
transcription factor involved in protection against fibrosis
[11]. Recently it has been also suggested that DHA, and in
particular two active metabolites derived from it, resolvins
and protectins, can modulate the inflammatory response
not only by decreasing cytokine production but also with
promotion of the resolution of inflammation [12]. Indeed,
animal models showed that these mediators might re-
duce inflammation induced by excessive adipose tissue
and improve insulin resistance, stimulating adiponectin
expression [12].
Furthermore, considering the importance of the gut-
liver axis in the development and progression of NAFLD,
a significant result, derived from animal models, suggests
that DHA could be effective in enhancing intestinal bar-
rier integrity, by increasing, for example, protein expres-
sion of intestinal tight junction proteins [12]. It seems to
be a bi-directional relationship between DHA and gut
microbiota: DHA may alter the gut microbial populations,
and some microbial species such as Bifidobacterium may
improve the tissue distribution of DHA [12].
Conclusions
In conclusion, DHA might exert a positive role in treat-
ment of NAFLD in pediatric age but it remains to be
demonstrated. Further well designed randomized con-
trolled trials are needed to better clarify the possible effi-
cacy of DHA treatment, and underlying mechanisms, in
obese children with NAFLD, to identify the optimal re-
quired dose and to evaluate if the DHA effect is limited
to the duration of the treatment or it may continue after
the end of treatment.Abbreviations
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